hyperuricemia
Conditions
Interventions
group 1:IBI362 drug
Sponsors
The First Affiliated Hospital of Henan University of Science and Technology
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18 to 60 years (including both ends), male or female; 2. Obese: BMI>=28.0kg/m2; or overweight: 24.0420umol/L; 4. Be able to understand the procedures and methods of this study, be willing to strictly follow the clinical trial protocol to complete this trial, and voluntarily sign the informed consent.
Exclusion criteria
Exclusion criteria: 1. The investigator suspects that the subject may be allergic to the study drug or ingredient or similar drugs; 2. Weight change >5.0% controlled by simple diet and exercise for at least 12 weeks before screening (complaint); 3. Subjects with secondary hyperuricemia; 4. Previously diagnosed as gout; 5. Use of any of the following drugs or treatments before screening: GLP-1 receptor (GLP-1R) agonist or GLP-1R/GCGR agonist or GIPR/GLP-1R agonist or GIPR/GLP-1R agonist within 3 months before screening GIPR/GLP-1R/GCGR agonist; used uric acid-lowering drugs within 3 months before screening, including allopurinol, febuxostat, benzbromarone, etc.; used within 3 months before screening, which has an effect on body weight medications, including: systemic steroids (intravenous, oral, or intraarticular), tricyclic antidepressants, psychiatric medications, or sedatives (eg, imipramine, amitriptyline, mirtazapine) , paroxetine, phenelzine, chlorpromazine, thioridazine, clozapine, olanzapine, valproic acid, valproic acid derivatives, lithium salts), etc.; used within 3 months before screening. Chinese herbal medicines, health products, meal replacements, etc.; have used or are currently using weight loss drugs within 3 months before screening, such as: sibutramine hydrochloride, orlistat, phentermine, phenylpropanolamine, chlorbenzidine Indole, phentermine, bupropion, lorcaserin, phentermine/topiramate mixture, naltrexone/bupropion mixture, etc.; used hypoglycemic drugs within 3 months before screening, such as metformin, SGLT2 inhibitors, thiazolidinediones (TZDs), etc.; participated in other clinical trials within 3 months before screening (received experimental drug treatment); 6. History or evidence of any of the following diseases: HbA1c >= 6.5% at screening or previously diagnosed with type I or type II diabetes; fasting venous blood glucose >= 7.0 mmol/L at screening; Retinopathy in the past or at screening Patients; previous severe hypoglycemia or recurrent symptomatic hypoglycemia (>=2 times within half a year); secondary disease or drug-induced obesity, including: elevated cortisol hormones (eg: Cushing's syndrome), pituitary and hypothalamus Obesity due to injury, obesity due to reduction/discontinuation of diet pills, etc.; previous weight loss surgery (except for acupuncture weight loss, liposuction, and abdominal fat removal 1 year before screening); planned weight loss during the study period Surgery or acupuncture for weight loss, liposuction and abdominal fat removal, etc.; past history of moderate to severe depression; or past history of serious mental illness, such as schizophrenia, bipolar disorder, etc.; past suicidal tendencies or Suicidal behavior; uncontrolled hypertension within one month prior to screening, defined as: systolic blood pressure >= 160 mmHg and/or diastolic blood pressure >= 100 mmHg (stable for 1 month if using antihypertensive drugs); previous or screening malignancy Medical history (except for cured basal cell carcinoma of the skin and carcinoma in situ of the cervix); previous myocardial infarction, angina pectoris, acute or chronic heart failure, cardiomyopathy, or percutaneous coronary intervention, coronary artery bypass grafting, etc. Cardiac surgery or echocardiography showed significantly abnormal cardiac function and was not suitable for participation in this study after investigator assessment; hemorrhagic or ischemic stroke or transient ischemic attack occurred within 6 months before screenin
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| uric acid; | — |
Countries
China
Contacts
Public ContactJiang Hongwei
The First Affiliated Hospital of Henan University of Science and Technology
Outcome results
None listed